Search for:

Skip to content

Main Navigation

Navigate to Vor Bio Medical Affairs homepage

Our Areas of Focus
- Myasthenia Gravis (MG)
- Sjögren’s Disease (SjD)
Medical Congress Events
Publications
Sponsorships & Grants
Medical Information

Global Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (RemeMG)

Dallas, TX

|

2026

Focus:

Myasthenia Gravis (MG)

Location:

N/A

Our Areas of Focus
- Myasthenia Gravis (MG)
- Sjögren’s Disease (SjD)
Medical Congress Events
Publications

Sponsorships & Grants
Medical Information

© 2026 Vor Biopharma | Telitacicept is an investigational product that is not approved for use by the FDA, or any equivalent international regulator in respect of its use outside of China.

Privacy Policy
Terms of Use

By selecting “Yes,” you confirm that you are a U.S.-based healthcare professional and that you are accessing this site for scientific and medical information. This site is not intended for patients, caregivers, or non-U.S. audiences.